PSI Advisors LLC Sells 1,400 Shares of Bristol-Myers Squibb (NYSE:BMY)

PSI Advisors LLC lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.5% during the 4th quarter, HoldingsChannel reports. The firm owned 4,550 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the period. PSI Advisors LLC’s holdings in Bristol-Myers Squibb were worth $257,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BMY. Thoroughbred Financial Services LLC raised its holdings in shares of Bristol-Myers Squibb by 9.5% during the second quarter. Thoroughbred Financial Services LLC now owns 10,353 shares of the biopharmaceutical company’s stock worth $430,000 after acquiring an additional 901 shares during the period. Envestnet Asset Management Inc. raised its stake in shares of Bristol-Myers Squibb by 1.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 2,268,887 shares of the biopharmaceutical company’s stock valued at $94,227,000 after purchasing an additional 34,643 shares during the period. Bcwm LLC bought a new stake in shares of Bristol-Myers Squibb in the second quarter valued at about $4,720,000. Keene & Associates Inc. boosted its position in shares of Bristol-Myers Squibb by 2.1% during the second quarter. Keene & Associates Inc. now owns 60,313 shares of the biopharmaceutical company’s stock worth $2,505,000 after buying an additional 1,249 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Bristol-Myers Squibb during the second quarter worth about $7,721,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Samit Hirawat purchased 1,830 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Down 0.9 %

BMY stock opened at $55.35 on Tuesday. The business’s 50 day simple moving average is $57.44 and its 200 day simple moving average is $51.66. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.08. The firm has a market capitalization of $112.26 billion, a PE ratio of -15.42, a PEG ratio of 15.20 and a beta of 0.45. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 earnings per share. As a group, research analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.48%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -69.08%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Citigroup boosted their target price on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, November 12th. Wolfe Research initiated coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They issued a “peer perform” rating on the stock. Bank of America reaffirmed a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Finally, BMO Capital Markets raised their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $56.27.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.